Cybin
CYBN
About: Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
Employees: 50
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
347% more call options, than puts
Call options by funds: $1.2M | Put options by funds: $268K
40% more capital invested
Capital invested by funds: $49.6M [Q1] → $69.5M (+$19.9M) [Q2]
0% more funds holding
Funds holding: 56 [Q1] → 56 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
1.22% less ownership
Funds ownership: 37.22% [Q1] → 36.0% (-1.22%) [Q2]
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
Canaccord Genuity
Sumant Kulkarni
|
$70
|
Buy
Maintained
|
8 Jul 2025 |
Financial journalist opinion
Based on 12 articles about CYBN published over the past 30 days
